Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using ¹⁷⁷Lu-iPSMA and ¹⁷⁷Lu-DOTATOC: Experience after 905 Treatment Doses

• Prif Awduron: Myrna Luna-Gutiérrez (Awdur), Rodrigo Hernández-Ramírez (Awdur), Airam Soto-Abundiz (Awdur), Osvaldo García-Pérez (Awdur), Alejandra Ancira-Cortez (Awdur), Sergio López-Buenrostro (Awdur), Brenda Gibbens-Bandala (Awdur), Irma Soldevilla-Gallardo (Awdur), Nancy Lara-Almazán (Awdur), Melissa Rojas-Pérez (Awdur), Blanca Ocampo-García (Awdur), Erika Azorín-Vega (Awdur), Clara Santos-Cuevas (Awdur), Guillermina Ferro-Flores (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: MDPI AG, 2023-07-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

¹⁷⁷Lu-iPSMA is a novel radioligand developed at ININ-Mexico with a high affinity for the PSMA protein heavily expressed in cancer cells of approximately 95% of patients with metastatic castration-resistant prostate cancer (mCRPC). ¹⁷⁷Lu-DOTATOC is a pate...